Drug Overview
Novartis has developed Arcapta (indacaterol; marketed as Onbrez outside the US) for use in its Breezhaler/Neohaler dry-powder inhaler for the treatment of chronic obstructive pulmonary disease (COPD). As the first once-daily long-acting beta 2 agonist (LABA) to launch in the COPD market, Arcapta has seen high use as an add-on therapy to the gold-standard long-acting muscarinic antagonist (LAMA), Spiriva (tiotropium; Boehringer Ingelheim). Due to the increasing availability of fixed-dose LABA/LAMA combination therapies, including Sunovion and Novartis’s Utibron Neohaler ([indacaterol + glycopyrrolate]), and a number of triple-combination therapies having been launched, the author does not forecast Arcapta to continue being used as an add-on therapy to Spiriva or other LAMA monotherapies. Instead, Arcapta is expected to be predominantly used as a monotherapy in mild and moderate patients.
Novartis has developed Arcapta (indacaterol; marketed as Onbrez outside the US) for use in its Breezhaler/Neohaler dry-powder inhaler for the treatment of chronic obstructive pulmonary disease (COPD). As the first once-daily long-acting beta 2 agonist (LABA) to launch in the COPD market, Arcapta has seen high use as an add-on therapy to the gold-standard long-acting muscarinic antagonist (LAMA), Spiriva (tiotropium; Boehringer Ingelheim). Due to the increasing availability of fixed-dose LABA/LAMA combination therapies, including Sunovion and Novartis’s Utibron Neohaler ([indacaterol + glycopyrrolate]), and a number of triple-combination therapies having been launched, the author does not forecast Arcapta to continue being used as an add-on therapy to Spiriva or other LAMA monotherapies. Instead, Arcapta is expected to be predominantly used as a monotherapy in mild and moderate patients.
Table of Contents
OVERVIEW
LIST OF FIGURES
LIST OF TABLES
